

DOCKET NO.: UPN-4023



PATENT

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SEP 19 2001

TECH CENTER 1600.2900

In Re Application of:
Mahalingam et al.

Serial No.: 09/485,421

Group Art Unit: 1632

Filing Date: October 5, 2000

Examiner: Q. Li

For: FUNCTIONAL FRAGMENTS OF HIV-1 VPR PROTEIN AND METHODS OF
USING THE SAME

DATE OF DEPOSIT: 13 SEPTEMBER 2001

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, DC 20231.

Paul K. Legaard
TYPED NAME: Paul K. Legaard
REGISTRATION NO.: 38,534

Box ☐ NON-FEE

☐ AF

Assistant Commissioner for Patents
Washington DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- ☐ A Preliminary Amendment.
- ☒ An Amendment and Response to Office Communication Dated August 15, 2001.
- ☐ An Amendment Supplemental to the Paper filed _____.
- ☐ Other: _____.

- ☐ Applicant(s) has previously claimed small entity status under 37 CFR §1.27.
- ☐ Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR §1.27 as:
- ☐ an Independent Inventor
 - ☐ a Small Business Concern
 - ☐ a Nonprofit Organization
- ☐ This application is no longer entitled to small entity status. It is requested that this be noted in the files of the Patent and Trademark Office.
- ☐ Substitute Pages _____ of the Specification are enclosed.
- ☐ An Abstract is enclosed.
- ☐ _____ Sheets of Proposed Corrected Drawings are enclosed.
- ☐ A Certified Copy of each of the following applications: _____ is enclosed.
- ☐ An Associate Power of Attorney is enclosed.
- ☐ Information Disclosure Statement.
- ☐ Attached Form 1449.
 - ☐ A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.
- ☐ Appended Material as follows: _____
- ☒ Other Material as follows: Response to Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosure; copy of Notice to Comply; Sequence Listing (10 pages); Statement to Support Filing of Sequence Listing; Computer Readable Diskette .

FEE CALCULATION

☒ No Additional Fee is Due.

				SMALL ENTITY		NOT SMALL ENTITY	
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	27	27 (20 MINIMUM)	0	\$9 EACH	\$	\$18 EACH	\$0
INDEP. CLAIMS	9	9 (3 MINIMUM)	0	\$40 EACH	\$	\$80 EACH	\$0
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$135	\$	\$270	\$0
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$55	\$	\$110	\$0
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$195	\$	\$390	\$0
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$445	\$	\$890	\$0
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$695	\$	\$1390	\$0
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$945	\$	\$1890	\$0
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$0)
<input type="checkbox"/> TERMINAL DISCLAIMER				\$55	\$	\$110	\$0
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							0
TOTAL FEE DUE							\$0


- ☐ A Check is Enclosed in the Foregoing Amount Due.
- ☐ Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Office Action of @@ to and through @@ comprising an extension of the shortened statutory period of @@ month(s).
- ☒ The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit

account 23-3050. This sheet is provided in duplicate.

- ☒ The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.
- ☐ The Foregoing Amount Due for Filing this Paper.
- ☒ Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
- ☒ Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: 13 SEPTEMBER 2001


Paul K. Legaard
Registration No. 38,534

Woodcock Washburn Kurtz
Mackiewicz & Norris LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

DOCKET NO.: UPN-4023



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mahalingam et al.

Serial No.: 09/485,421

Group Art Unit: 1632

Filed: October 5, 2000

Examiner: Q. Li


RECEIVED

TECH CENTER 1600 2900

For: **FUNCTIONAL FRAGMENTS OF HIV-1 VPR PROTEIN AND METHODS
OF USING THE SAME**

I, Paul K. Legaard, Registration No. 38,534 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On September 13, 2001


Paul K. Legaard Reg. No. 38,534

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

AMENDMENT AND RESPONSE TO OFFICE COMMUNICATION

The present Amendment is filed in response to the Office Communication mailed August 15, 2001 in connection with the above-identified patent application. Applicants respectfully request that the application be amended prior to examination on the merits as indicated below.

In the Application:

Please add new pages 1-10 which contain the Sequence Listing formatted under the new rules for the Sequence Listing.

REMARKS

As a preliminary matter, the Attorney Docket No. of the present application has been changed to "UPN-4023." In addition, Applicants acknowledge receipt of the paper outlining changes